Hemophilia drug under microscope: does it really keep joints safe?
NCT ID NCT07420348
First seen Feb 24, 2026 · Last updated May 14, 2026 · Updated 11 times
Summary
This study looks at whether emicizumab, a drug for hemophilia A, can prevent early joint damage that isn't visible to the naked eye. About 70 people will have their elbows, knees, and ankles checked with ultrasound at the start, then again after 1 and 2 years. The goal is to see how often damage appears in joints that were initially healthy, helping doctors understand how well the drug protects joints over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Universidad de Oviedo
Oviedo, Principality of Asturias, 33006, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.